Anika Therapeutics, Inc.
ANIK · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $242,308 | $332,105 | $431,006 | $515,988 |
| - Cash | $55,629 | $72,867 | $86,327 | $94,386 |
| + Debt | $25,932 | $29,037 | $30,890 | $20,954 |
| Enterprise Value | $212,611 | $288,275 | $375,569 | $442,556 |
| Revenue | $119,907 | $120,792 | $113,827 | $147,794 |
| % Growth | -0.7% | 6.1% | -23% | – |
| Gross Profit | $75,998 | $82,532 | $73,220 | $82,943 |
| % Margin | 63.4% | 68.3% | 64.3% | 56.1% |
| EBITDA | $3,020 | $15,061 | $18,157 | -$4,163 |
| % Margin | 2.5% | 12.5% | 16% | -2.8% |
| Net Income | -$56,385 | -$82,667 | -$14,859 | $4,134 |
| % Margin | -47% | -68.4% | -13.1% | 2.8% |
| EPS Diluted | -3.83 | -5.64 | -1.02 | 0.28 |
| % Growth | 32.1% | -452.9% | -464.3% | – |
| Operating Cash Flow | $5,403 | -$1,788 | $4,409 | $8,397 |
| Capital Expenditures | -$7,734 | -$5,427 | -$7,486 | -$5,143 |
| Free Cash Flow | -$2,331 | -$7,215 | -$3,077 | $3,254 |